Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Hybrigenics    ALHYG   FR0004153930

HYBRIGENICS

(ALHYG)
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Real-time Quote. Real-time Euronext Growth Paris
02/25/2021 02/26/2021 03/01/2021 03/02/2021 03/03/2021 Date
0.282(c) 0.34(c) 0.43(c) 0.4005(c) 0.354(c) Last
23 706 525 42 116 170 53 233 812 31 577 473 19 041 932 Volume
+9.30% +20.57% +26.47% -6.86% -11.61% Change
More quotes
Company
Hybrigenics is a biopharmaceutical company. Hybrigenics and its subsidiaries constitute the DMS Biotech division, which carries the development strategy of DMS (Diagnostic Medical Systems) in the field of biotechnologies, particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells. Hybrigenics and Servier collaborated on a specific ubiquitin... 
More about the company
All news about HYBRIGENICS
2018HYBRIGENICSá : Half-year results
CO
2018HYBRIGENICSá : Annual results
CO
2017HYBRIGENICSá : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) an..
PU
2017HYBRIGENICSá : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 2..
PU
2017HYBRIGENICSá : gets European patent protection for inhibitors of Ubiquitin-Speci..
PU
2017HYBRIGENICSá : full year 2016 results
PU
2017HYBRIGENICSá : Strategic refocusing on biopharmaceutical R&D
PU
2017HYBRIGENICSá : Encouraging preliminary results of the Phase II clinical study of..
PU
2017HYBRIGENICS'á : patent estate of inhibitors of ubiquitin specific proteases cont..
PU
2016HYBRIGENICSá : rsquo; inecalcitol strengthens key patent protection in the Unite..
PU
2016HYBRIGENICSá : receives green light for a double-blind placebo-controlled Phase ..
PU
2014HYBRIGENICSá : 2014 first-half results and highlights
PU
2014HYBRIGENICSá : successfully raised Ç 4.6 million
PU
2014HYBRIGENICSá : invests in its genomic capabilities
PU
2014HYBRIGENICS'á : patent estate of inhibitors of ubiquitin-specific proteases is e..
PU
More news
News in other languages on HYBRIGENICS
2020EN DIRECT DES MARCHESá : Unibail, Sodexo, Sanofi, Imerys, Fnac Darty, Solocal, R..
2020HYBRIGENICSá : Comptes et Annexes
2020HYBRIGENICSá : Résultats semestriels 2020
2020HYBRIGENICSá : DMS Biotech participe à l'effort collectif contre le coronavirus
2020HYBRIGENICSá : Développement à Hong Kong avec le partenaire WKK International Li..
More news
Chart HYBRIGENICS
Duration : Period :
Hybrigenics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYBRIGENICS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Managers and Directors
NameTitle
Julien Gauthier Chief Executive Officer
Jean-Paul Ansel Chairman
Jean-Franšois Dufour-Lamartinie Director-Clinical Research & Development
Philippe Nerin Independent Director
See-Nuan Simonyi Director
Sector and Competitors
1st jan.Capitalization (M$)
HYBRIGENICS59.10%100
MODERNA, INC.40.53%58 690
LONZA GROUP AG1.62%46 935
IQVIA HOLDINGS INC.6.37%36 961
CELLTRION, INC.-15.60%35 341
SEAGEN INC.-15.54%27 847